0byt3m1n1-V2
Path:
/
home
/
nlpacade
/
www.OLD
/
arcanepnl.com
/
rocinante-one-jzez
/
cache
/
[
Home
]
File: 15531ccf0dcc6f314d8ce1e7d9bd73e2
a:5:{s:8:"template";s:7947:"<!DOCTYPE html> <html lang="en"> <head> <meta charset="utf-8"/> <meta content="width=device-width, initial-scale=1, maximum-scale=1" name="viewport"/> <title>{{ keyword }}</title> <link href="http://fonts.googleapis.com/css?family=Montserrat%3A1%2C300%2C400%2C400italic%2C700&ver=4.8.12" id="Montserrat-css" media="all" rel="stylesheet" type="text/css"/> <link href="http://fonts.googleapis.com/css?family=Lato%3A1%2C300%2C400%2C400italic%2C700&ver=4.8.12" id="Lato-css" media="all" rel="stylesheet" type="text/css"/> <style rel="stylesheet" type="text/css"> .rev-scroll-btn>:focus,.rev-scroll-btn>:hover{color:#fff}.rev-scroll-btn>:active,.rev-scroll-btn>:focus,.rev-scroll-btn>:hover{opacity:.8}a,body,div,footer,h2,header,html,li,nav,span,ul{margin:0;padding:0;border:0;font-size:100%;font:inherit;vertical-align:baseline}footer,header,nav{display:block}body{line-height:1}ul{list-style:none}html{height:100%}body{-webkit-font-smoothing:antialiased;-webkit-text-size-adjust:100%}h2{margin-bottom:15px}a,a:focus,a:visited{text-decoration:none;outline:0}a:hover{text-decoration:underline} body{min-width:960px}#Wrapper{max-width:1240px;margin:0 auto;overflow:hidden;-webkit-box-shadow:0 0 15px rgba(0,0,0,.06);box-shadow:0 0 15px rgba(0,0,0,.06)}.layout-full-width{padding:0}.layout-full-width #Wrapper{max-width:100%!important;width:100%!important;margin:0!important}.container{max-width:1220px;margin:0 auto;position:relative}.container:after{clear:both;content:" ";display:block;height:0;visibility:hidden}.column{float:left;margin:0 1% 40px}.one.column{width:98%}.container:after{content:"\0020";display:block;height:0;clear:both;visibility:hidden}.clearfix:after,.clearfix:before{content:'\0020';display:block;overflow:hidden;visibility:hidden;width:0;height:0}.clearfix:after{clear:both}.clearfix{zoom:1}#Header{position:relative}#Top_bar{position:absolute;left:0;top:61px;width:100%;z-index:30}#Top_bar .column{margin-bottom:0}#Top_bar .top_bar_left{position:relative;float:left;width:990px}#Top_bar .logo{float:left;margin:0 30px 0 20px}#Top_bar .menu_wrapper{float:left;z-index:201}#Top_bar .secondary_menu_wrapper{display:none}#Top_bar .banner_wrapper{display:none}#Top_bar #menu{z-index:201}#Top_bar .menu{z-index:202}#Top_bar .menu>li{margin:0;z-index:203;display:block;float:left}#Top_bar .menu>li:not(.mfn-megamenu-parent){position:relative}#Top_bar .menu>li>a{display:block;line-height:60px;padding:15px 0;position:relative}#Top_bar .menu>li>a:after{content:"";height:4px;width:100%;position:absolute;left:0;top:-4px;z-index:203;opacity:0}#Top_bar .menu>li>a span:not(.description){display:block;line-height:60px;padding:0 20px;white-space:nowrap;border-right-width:1px;border-style:solid}#Top_bar .menu>li:last-child>a span{border:0}#Top_bar .menu>li>a:hover{text-decoration:none}#Top_bar .menu>li>a,#Top_bar .menu>li>a:after{-webkit-transition:all .3s ease-in-out;-moz-transition:all .3s ease-in-out;-o-transition:all .3s ease-in-out;-ms-transition:all .3s ease-in-out;transition:all .3s ease-in-out}.header-plain #Top_bar{border-bottom-width:1px;border-style:solid;position:static}.header-plain #Top_bar .one.column{width:100%;margin:0}.header-plain #Header .top_bar_left{background-color:transparent}.header-plain #Top_bar .menu_wrapper{float:right}.header-plain #Top_bar .menu>li>a{padding-top:0!important;padding-bottom:0!important}.header-plain #Top_bar .menu>li>a:after{display:none}.header-plain #Top_bar .menu>li>a span:not(.description){line-height:80px;padding:0 30px}.header-plain #Top_bar .menu>li:first-child>a span:not(.description){border-left-width:1px}.header-plain.menu-highlight #Top_bar .menu>li,.header-plain.menu-highlight #Top_bar .menu>li>a{margin:0}.header-plain #Top_bar .menu>li>a span:not(.description){line-height:80px;padding:0 30px}.header-plain #Top_bar{background-color:#fff}.header-plain #Top_bar,.header-plain #Top_bar .menu>li>a span:not(.description){border-color:#f2f2f2}#Footer{background-position:center top;background-repeat:no-repeat;position:relative}#Footer .footer_copy{border-top:1px solid rgba(255,255,255,.1)}#Footer .footer_copy .one{margin-bottom:20px;padding-top:30px;min-height:33px}#Footer .footer_copy .copyright{float:left}#Footer .footer_copy .social{float:right;margin-right:20px}ul{list-style:none outside}::-moz-selection{color:#fff}::selection{color:#fff}#Top_bar .menu>li>a span{border-color:rgba(0,0,0,.05)}body,html{overflow-x:hidden}@media only screen and (min-width:960px) and (max-width:1239px){body{min-width:0}#Wrapper{max-width:960px}.container{max-width:940px}#Top_bar .top_bar_left{width:729px}}@media only screen and (min-width:768px) and (max-width:959px){body{min-width:0}#Wrapper{max-width:728px}.container{max-width:708px}#Top_bar .top_bar_left{width:501px}}@media only screen and (min-width:768px){.header-plain #Top_bar,.header-plain #Top_bar .menu>li>a span:not(.description){border-color:rgba(255,255,255,.1)}}@media only screen and (max-width:767px){body{min-width:0}#Wrapper{max-width:90%;max-width:calc(100% - 67px)}.container .column{margin:0;width:100%!important;clear:both}.container{max-width:700px!important;padding:0 33px!important}body:not(.mobile-sticky) .header_placeholder{height:0!important}#Top_bar{background:#fff!important;position:static}#Top_bar .container{max-width:100%!important;padding:0!important}#Top_bar .top_bar_left{float:none;width:100%!important;background:0 0!important}#Top_bar .menu_wrapper{float:left!important;width:100%;margin:0!important}#Top_bar #menu{float:left;position:static!important;width:100%!important;padding-bottom:20px}#Top_bar .logo{position:static;float:left;width:100%;text-align:center;margin:0}.header-plain #Top_bar .logo{text-align:left}#Footer .footer_copy{text-align:center}#Footer .footer_copy .copyright{float:none;margin:0 0 10px}#Footer .footer_copy .social{float:none;margin:0}} @font-face{font-family:Montserrat;font-style:normal;font-weight:400;src:local('Montserrat Regular'),local('Montserrat-Regular'),url(http://fonts.gstatic.com/s/montserrat/v14/JTUSjIg1_i6t8kCHKm459Wlhzg.ttf) format('truetype')} @font-face{font-family:Lato;font-style:normal;font-weight:400;src:local('Lato Regular'),local('Lato-Regular'),url(http://fonts.gstatic.com/s/lato/v16/S6uyw4BMUTPHjx4wWw.ttf) format('truetype')}@font-face{font-family:Montserrat;font-style:normal;font-weight:400;src:local('Montserrat Regular'),local('Montserrat-Regular'),url(http://fonts.gstatic.com/s/montserrat/v14/JTUSjIg1_i6t8kCHKm459Wlhzg.ttf) format('truetype')}</style> </head> <body class=" color-custom style-simple layout-full-width nice-scroll-on header-plain minimalist-header sticky-header sticky-white ab-hide subheader-both-center menu-highlight menuo-no-borders menuo-right mobile-tb-hide mobile-mini-mr-ll"> <div id="Wrapper"> <div class="bg-parallax"> <header id="Header"> <div class="header_placeholder"></div> <div class="loading" id="Top_bar"> <div class="container"> <div class="column one"> <div class="top_bar_left clearfix"> <div class="logo"><h2>{{ keyword }}</h2></div> <div class="menu_wrapper"> <nav class="menu-main-menu-container" id="menu"><ul class="menu" id="menu-main-menu"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home" id="menu-item-64"><a href="#"><span>Home</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page" id="menu-item-108"><a href="#"><span>FAQ</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page" id="menu-item-104"><a href="#"><span>Contact</span></a></li> </ul></nav> </div><div class="secondary_menu_wrapper"> </div> <div class="banner_wrapper"> </div> </div> </div> </div> </div> </header> </div> {{ text }} <br> <br> {{ links }} <footer class="clearfix" id="Footer"> <div class="footer_copy"> <div class="container"> <div class="column one"> <div class="copyright"> {{ keyword }} 2021</div> <ul class="social"></ul> </div> </div> </div> </footer> </div> </body> </html>";s:4:"text";s:9979:"Thus, it appears that the use of estramustine with docetaxel in advanced prostate cancer is not necessary and may be detrimental. Taxane chemotherapy is also effective in prolonging life in patients who have a high burden of cancer on scans when starting hormonal therapy for the first time for metastatic disease. Please enable it to take advantage of the complete set of features! Amato RJ, Teh BS, Henary H, Khan M, Saxena S. Urol Oncol. | As the Prostate Cancer Clinical Trials Working Group 3 has noted, localized PC progresses to biomedical recurrence or to mHSPC, both of which ultimately become resistant to hormone therapy and are potential candidates for successive treatments. This is good news, but we know it has raised lots of questions for men with advanced prostate cancer. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Berthold DR, Pond GR, Soban F, et al. Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer, with recent data showing profound benefits with docetaxel in newly diagnosed patients. Chemotherapy is sometimes used when cancer has spread beyond the prostate gland and hormone therapies have failed to control it. These showed that giving chemotherapy earlier, at the same time as hormone therapy, to men whose prostate cancer has spread beyond the prostate and the surrounding area, can help keep them alive for longer. Department of Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH 44195, USA, To place appropriately into context the current status of chemotherapy as a management Taxane chemotherapy agents approved for the treatment of advanced prostate cancer include docetaxel (Taxotere®) and cabazitaxel (Jevtana®). Key words Prostate cancer, docetaxel (Taxotere®), chemotherapy. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. Epothilones: mechanism of action and biologic activity. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. Curr Opin Urol. The case for early chemotherapy for the treatment of metastatic disease. Advanced prostate cancer is a cancer that began in the prostate and has spread to another part of the body. Jong Chul Park, MD, Mario Eisenberger, MD. We have previously shown that time to nadir (TTN) of prostate-specific antigen (PSA) is an important prognostic factor in patients from a single center in Northwestern China. J Clin Oncol. Comparison of the efficacy of local therapies for localized prostate cancer in the PSA era: a large single insitution experience with radical prostatectomy and external beam radiotherapy. Prostate cancer chemotherapy may also be used to treat pain caused by cancer that has spread to the bone. The drug is well tolerated and may be able to target hormonally resistant cells, complimenting the abilities of androgen suppression to target hormonally sensitive cells. Crossref; PubMed ; Scopus (4410) Google Scholar]. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. J Clin Oncol 2008; 26:4049. Chemotherapy uses anti-cancer (cytotoxic) drugs to destroy cancer cells. option for patients with hormone-refractory metastatic prostate cancer (HRMPC), it Metastatic prostate cancer includes stage 4 and recurrent disease when the cancer has spread beyond the tissues surrounding the prostate to other parts of the body. Your account has been temporarily locked. We use cookies to help provide and enhance our service and tailor content and ads. © 2006 Elsevier Inc. 2008 May;18(3):263-8. doi: 10.1097/MOU.0b013e3282f9b37f. first chemotherapy agent to improve overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC).15,16 In the CHAARTED trial (ClinicalTrials.gov identifier NCT00309985) investigating the combina-tion of docetaxel with ADT versus ADT alone in 790 patients with metastatic prostate cancer not previously Docetaxel as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Locally advanced prostate cancer extends beyond the capsule of the prostate and is often asymptomatic when diagnosed. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. However, 2010 has proven to be a landmark year for prostate cancer therapy, with the results of several phase III trials demonstrating improvements in survival with novel therapies. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?. Yagoda and Petrylak evaluated the results of 26 phase II trials of antineoplastics in advanced prostate cancer published between 1987 and 1991 and found the average objective response rate was less than 10% with only a few studies having response rates in the 10% to 20%range. Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells. Yagoda and Petrylak [. PSA is a substance produced within the prostate gland, and a high PSA level may indicate the presence of cancer. is important to reflect on the widely held historical belief that advanced prostate Berthold DR, Pond GR, Soban F, et al. Hematol ... progressive prostate cancer after frontline chemotherapy; and (3) locally advanced prostate cancer. Background Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. The treatment landscape of advanced prostate cancer is changing rapidly. This site needs JavaScript to work properly. Would you like email updates of new search results? Advanced prostate cancer is prostate cancer that has spread to other parts of the body, beyond the prostate gland. If you’ve just been diagnosed with advanced prostate cancer, you might be offered chemotherapy at the same time as, or soon after, you start another treatment called hormone therapy. 0 ng/mL, and WHO performance status score of 0–2), had received no chemotherapy (except with estramustine), had undergone surgical or chemical castration, and had been referred to a treatment centre in Finland, Ireland, or Sweden. Clinical states in prostate cancer: toward a dynamic model of disease progression. In addition to prostate cancer, Taxotere may be used for people with some kinds of lung cancer, breast cancer… Since cancer cells are some of the most rapidly dividing cells in the body, these cells are preferentially affected by the action of Taxotere and, consequently, … A Southwest Oncology Group Study (S0111). Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis? Prostate cancer is the second most commonly diagnosed cancer in men and a leading cause of cancer related deaths. Inhibition of prostate cancer growth by estrmustine and etoposide: evidence for interaction at the nuclear matrix. Sanfilippo NJ, Taneja SS, Chachoua A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San 2014 Sep;33(2-3):399-411. doi: 10.1007/s10555-013-9471-3. It is used with the purpose of blocking the growth of the tumor, as it acts on the cancerous cells, preventing them from separating into two new cells. To read this article in full you will need to make a payment. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. ALEXANDRIA, Va. – A new analysis of the ongoing STAMPEDE clinical trial found that adding the chemotherapy drug docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Additionally, it covers how new approaches may help decrease the morbidity associated with advanced prostate cancer. It may also be used to treat cancer that is no longer being controlled by hormonal therapy. The chemotherapy drug docetaxel (Taxotere) taken with or without prednisone (a steroid) is the standard chemotherapy regimen for patients who no longer respond to hormone therapy. For many years, sequential hormonal manipulations, including estramustine phosphate, radiotherapy, and mitoxantrone were the only available options, aiming essentially at relieving pain and improving quality of life. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Docetaxel works by preventing cancer cells from dividing and growing. ";s:7:"keyword";s:63:"chemotherapy for advanced prostate cancer: docetaxel and beyond";s:5:"links";s:1144:"<a href="http://arcanepnl.com/rocinante-one-jzez/indian-wool-blankets-7d102b">Indian Wool Blankets</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/eu4-humiliate-vs-show-strength-7d102b">Eu4 Humiliate Vs Show Strength</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/jackson-odell-icarly-role-7d102b">Jackson Odell Icarly Role</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/atv-sound-systems-7d102b">Atv Sound Systems</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/kidkraft-so-chic-dollhouse-instructions-7d102b">Kidkraft So Chic Dollhouse Instructions</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/necron-eradication-legion-7d102b">Necron Eradication Legion</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/nutrition-quackery-websites-7d102b">Nutrition Quackery Websites</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/mace-river-ranch-subdivision-7d102b">Mace River Ranch Subdivision</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/sweet-tooth-song-in-russian-7d102b">Sweet Tooth Song In Russian</a>, <a href="http://arcanepnl.com/rocinante-one-jzez/parx-play-plus-7d102b">Parx Play Plus</a>, ";s:7:"expired";i:-1;}
©
2018.